All Drug Development articles
-
NewsRAGE receptor identified as key driver of age-related metastasis
Georgetown Lombardi researchers have identified RAGE, an inflammatory receptor, as a key mediator of age-related breast cancer metastasis.
-
NewsMYC protein found to repair DNA in cancer cells
Oregon Health & Science University researchers have identified a non-canonical function of the MYC oncoprotein in DNA damage repair, revealing how tumour cells survive chemotherapy-induced stress.
-
NewsMitochondrial fission activation offers new tool in fight against antibiotic resistance
Scientists at The University of Queensland have discovered that activating mitochondrial fission can enhance immune defences against antibiotic-resistant bacteria.
-
NewsCAR T cell therapy eliminates glioblastoma tumours in preclinical study
A next-generation CAR T cell immunotherapy targeting the urokinase receptor has eliminated treatment-resistant glioblastoma tumours in preclinical models.
-
NewsAI system transforms weak antibiotics into powerful treatments
University of Pennsylvania researchers have developed ApexGO, an AI system that refines imperfect antibiotic candidates through calculated modifications rather than database screening.
-
NewsNew malaria drug T111 targets all parasite stages in single treatment
A novel compound developed over 15 years of research has demonstrated unprecedented activity against liver, blood and sexual stages of Plasmodium parasites, possibly positioning it as a potential cure for malaria.
-
NewsAI system reduces animal testing in drug discovery by 50 percent
German researchers have developed genESOM, a generative AI system that could reduce animal numbers in preclinical drug testing by 30 to 50 percent.
-
NewsASGCT 2026 Annual Meeting Opens in Boston this week
The American Society of Gene & Cell Therapy’s 2026 Annual Meeting opens in Boston on 11 May, bringing together thousands of researchers, clinicians and industry leaders for five days of scientific programming.
-
NewsOpenBind launches AI model to accelerate drug discovery
Diamond Light Source has launched OpenBind v1, an open-access AI model and dataset designed to address critical data shortages in drug discovery by providing standardised protein-drug binding measurements at atomic resolution.
-
NewsBispecific antibody targets Wnt co-receptors for diabetic macular oedema treatment
Preclinical data presented at ARVO 2026 demonstrate therapeutic potential of targeting Gpr124 and Lrp6 Wnt co-receptors to restore blood-retina barrier integrity in diabetic macular oedema and wet age-related macular degeneration, with trispecific candidate NVQ501 advancing towards IND-enabling studies.
-
ReportOrganoids and Organ Chips: Improving Decision-Making in Early Drug Discovery
Early drug discovery has no shortage of models, but predicting what will translate to patients remains difficult. This report examines how organoids, organ-on-chip systems and imaging technologies are used to measure drug response, analyse resistance mechanisms and assess how well findings reflect clinical outcomes in human-relevant models.
-
NewsMetal microrobots deliver drugs and biopsies before dissolving
Swallowable metal microrobots that transform shape to deliver drugs and collect tissue samples before safely dissolving could replace invasive endoscopy procedures.
-
NewsSafer diazo compound synthesis advances medicinal chemistry capabilities
Researchers at Tokyo University of Science have developed a safer synthetic route to β-heteroatom-substituted diazo esters, eliminating the need for toxic diazomethane. The azide-to-diazo conversion method uses mild conditions and readily available starting materials, potentially streamlining early-stage drug discovery and compound library synthesis.
-
NewsNew dual-action drug candidate extends survival in pancreatic cancer models
Researchers have developed a dual-mechanism compound that significantly extended survival in preclinical pancreatic cancer models by simultaneously activating immune responses and blocking suppressive pathways.
-
NewsHybrid molecule shows enhanced metabolic effects in obesity study
A novel hybrid molecule combining incretin therapy with targeted intracellular delivery of a PPAR agonist has demonstrated strong weight loss and glucose control compared to existing GLP-1/GIP therapies in preclinical studies.
-
NewsAAX Biotech and evitria partner on antibody development
AAX Biotech has partnered with evitria AG to expand access to its Opti-mAb® platform, enabling earlier integration of stability-enhancing technology into antibody candidate design and multispecific format development.
-
NewsRepurposed cancer drugs target root cause of Crohn’s Disease
Researchers at the University of Houston have identified epithelial stress signalling as a key driver of Crohn’s disease and demonstrated that two FDA-approved cancer drugs can interrupt the pathological cycle of cell death and inflammation.
-
ArticleFrom leaderboards to lab notebooks: AI designs reach preclinical testing
For years, AI drug discovery has been judged on benchmark performance. Now, a set of studies shows what happens when those designs are made and tested in preclinical settings.
-
NewsNew strategy targets antibiotic resistance in cystic fibrosis
Researchers at the University of Texas at Austin have demonstrated that targeting a bacterial protein-folding pathway can disable antimicrobial resistance and cross-protection, restoring antibiotic susceptibility in preclinical models of cystic fibrosis infection.
-
NewsCircio and Acuitas partner on circular RNA CAR T therapy
Norway-based biotechnology company Circio Holding ASA has partnered with Acuitas Therapeutics to evaluate its circVec circular RNA platform for in vivo CAR T cell therapy. The collaboration will combine Circio’s technology, which reportedly delivers gene expression lasting up to six months in lymphocytes, with Acuitas’ lipid nanoparticle delivery system targeting specific T cell populations for potential applications in oncology and autoimmune diseases.